AU · rank #20 · 2026-10-19
IMCD
AMSTERDAM · EUR · $6.90B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.338 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +12.8% |
| Momentum acceleration 3-month minus 12-month momentum. | +13.89% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $105.55 |
| Market cap (USD) | $6.90B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a global distributor and formulator of specialty chemicals and ingredients, providing local technical sales, application labs, regulatory assistance, and supply chain services.
Rationale
The analyst upside signal is supported by 100% positive EPS revision agreement and 12.8% target upside, validated by Q2 2026 organic gross profit growth recovering to 7% after a Q1 contraction.
Material risks
- 1Potential disintermediation if major specialty chemical producers or downstream customers internalize formulation, regulatory, and distribution capabilities.
- 2Margin compression from specialty chemical pricing weakness and elevated execution risk across bolt-on M&A with net debt at 2.8x operating EBITDA.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.